• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Multiple sclerosis risk sharing scheme: a costly failure.

作者信息

Raftery James

机构信息

Wessex Institute, School of Medicine, University of Southampton, Southampton SO167NS.

出版信息

BMJ. 2010 Jun 3;340:c1672. doi: 10.1136/bmj.c1672.

DOI:10.1136/bmj.c1672
PMID:20522654
Abstract
摘要

相似文献

1
Multiple sclerosis risk sharing scheme: a costly failure.多发性硬化症风险分担计划：代价高昂的失败。
BMJ. 2010 Jun 3;340:c1672. doi: 10.1136/bmj.c1672.
2
Commentary: Scheme has benefited patients.评论：该方案已使患者受益。
BMJ. 2010 Jun 3;340:c2707. doi: 10.1136/bmj.c2707.
3
The multiple sclerosis risk sharing scheme.多发性硬化症风险分担计划。
BMJ. 2010 Jun 3;340:c2882. doi: 10.1136/bmj.c2882.
4
Commentary: Outcome measures were flawed.评论：结果指标存在缺陷。
BMJ. 2010 Jun 3;340:c2693. doi: 10.1136/bmj.c2693.
5
Continuing the multiple sclerosis risk sharing scheme is unjustified.继续实施多发性硬化症风险分担计划是不合理的。
BMJ. 2010 Jun 3;340:c1786. doi: 10.1136/bmj.c1786.
6
Shared scheme for assessing drugs for multiple sclerosis: cost effective provision of effective treatments for multiple sclerosis.评估治疗多发性硬化症药物的共享方案：以具有成本效益的方式提供多发性硬化症的有效治疗。
BMJ. 2003 May 31;326(7400):1212. doi: 10.1136/bmj.326.7400.1212.
7
MS risk sharing scheme. Some clarification needed.多发性硬化症风险分担计划。需要一些澄清。
BMJ. 2010 Jul 7;341:c3589. doi: 10.1136/bmj.c3589.
8
Access denied. While the decision over beta-interferon prescribing hangs in the balance, one thing's for certain--nurses will be left to pick up the pieces.访问被拒绝。虽然关于β-干扰素处方的决定悬而未决，但有一件事是肯定的——护士将不得不收拾残局。
Nurs Stand. 2000;14(44):20. doi: 10.7748/ns.14.44.20.s40.
9
[Place of residence determines access to interferon-beta therapy in MS. Less than 15 per cent of patients are treated--big differences between the counties].[居住地决定了多发性硬化症患者获得β-干扰素治疗的机会。接受治疗的患者不到15%，各县之间存在很大差异]
Lakartidningen. 1999 Dec 8;96(49):5492-5.
10
Shared scheme for assessing drugs for multiple sclerosis: why are eyes tightly shut to considering causes other than autoimmunity?评估治疗多发性硬化症药物的共享方案：为何对考虑自身免疫以外的病因视而不见？
BMJ. 2003 May 31;326(7400):1213. doi: 10.1136/bmj.326.7400.1213.

引用本文的文献

1
A Comparative Analysis of Anticancer Drug Appraisals Including Managed Entry Agreements in South Korea and England.韩国和英国含管理准入协议的抗癌药物评估的对比分析。
Appl Health Econ Health Policy. 2023 Mar;21(2):347-359. doi: 10.1007/s40258-022-00778-1. Epub 2022 Dec 20.
2
Barriers and Opportunities for Implementation of Outcome-Based Spread Payments for High-Cost, One-Shot Curative Therapies.高成本一次性治愈性疗法实施基于结果的推广支付的障碍与机遇
Front Pharmacol. 2020 Dec 8;11:594446. doi: 10.3389/fphar.2020.594446. eCollection 2020.
3
Application of Managed Entry Agreements for Innovative Therapies in Different Settings and Combinations: A Feasibility Analysis.
管理准入协议在不同环境和组合下对创新疗法的应用：可行性分析。
Int J Environ Res Public Health. 2020 Nov 10;17(22):8309. doi: 10.3390/ijerph17228309.
4
Dynamic Learning of Patient Response Types: An Application to Treating Chronic Diseases.患者反应类型的动态学习：在慢性病治疗中的应用
Manage Sci. 2018 Aug;64(8):3469-3970. doi: 10.1287/mnsc.2017.2793. Epub 2017 Aug 21.
5
The Assessment for Disinvestment of Intramuscular Interferon Beta for Relapsing-Remitting Multiple Sclerosis in Brazil.巴西对用于治疗复发缓解型多发性硬化症的肌内干扰素β的去投资评估。
Pharmacoeconomics. 2018 Feb;36(2):161-173. doi: 10.1007/s40273-017-0579-0.
6
Drug approval status and recommendations for listing on public formularies: a Canadian cohort analysis.药物批准状态及列入公共处方集的建议：一项加拿大队列分析。
BMJ Open. 2017 Oct 22;7(10):e018372. doi: 10.1136/bmjopen-2017-018372.
7
Disease-Modifying Therapies for Multiple Sclerosis: A Systematic Literature Review of Cost-Effectiveness Studies.多发性硬化症的疾病修正治疗：成本效益研究的系统文献回顾。
Pharmacoeconomics. 2018 Feb;36(2):189-204. doi: 10.1007/s40273-017-0577-2.
8
Payers' Views of the Changes Arising through the Possible Adoption of Adaptive Pathways.支付方对可能采用适应性路径所带来变化的看法。
Front Pharmacol. 2016 Sep 28;7:305. doi: 10.3389/fphar.2016.00305. eCollection 2016.
9
Performance-Based Agreements in Italy: 'Trendy Outcomes' or Mere Illusions?意大利基于绩效的协议：“时髦的成果”还是纯粹的幻想？
Pharmacoeconomics. 2016 Oct;34(10):967-9. doi: 10.1007/s40273-016-0420-1.
10
Regulatory withdrawal of medicines marketed with uncertain benefits: the bevacizumab case study.对具有不确定获益的上市药品进行监管撤市：贝伐单抗案例研究
J Pharm Policy Pract. 2015 Oct 19;8:25. doi: 10.1186/s40545-015-0046-2. eCollection 2015.